Therapeutic effects on atopic dermatitis by anti-relA short interfering RNA combined with functional peptides Tat and AT1002

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 2, 2011, Pages 443-450

  Uchida, Tamae ^a   Kanazawa, Takanori ^a   Kawai, Misako ^a   Takashima, Yuuki ^a   Okada, Hiroaki ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AT 1002; CYTOKINE; DRUG CARRIER; IMMUNOGLOBULIN E; MESSENGER RNA; PEPTIDE DERIVATIVE; PROTEIN ZO1; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN DERIVATIVE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG TRANSPORT; EAR; EPIDERMIS; FEMALE; GENE SILENCING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THICKNESS;

ANIMALS; CELLS, CULTURED; DERMATITIS, ATOPIC; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; FEMALE; GENE PRODUCTS, TAT; GENE SILENCING; MALE; MICE; MICE, INBRED ICR; OLIGOPEPTIDES; RNA, SMALL INTERFERING; SKIN ABSORPTION; TRANSCRIPTION FACTOR RELA;

EID: 79960515375     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.180042     Document Type: Article

References (21)

1. Barnes PJ and Karin M (1997) Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071. (Pubitemid 27163860)
2. Becker JC, Houben R, Vetter CS, and Bröcker EB (2006) The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 6:7.
3. Chen SH and Zhaori G (2011) Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest 41:221-232.
4. Dajee M, Muchamuel T, Schryver B, Oo A, Alleman-Sposeto J, De Vry CG, Prasad S, Ruhrmund D, Shyamsundar R, Mutnick D, et al. (2006) Blockade of experimental atopic dermatitis via topical NF-κB decoy oligonucleotide. J Invest Dermatol 126: 1792-1803. (Pubitemid 44086514)
5. Fasano A, Fiorentini C, Donelli G, Uzzau S, Kaper JB, Margaretten K, Ding X, Guandalini S, Comstock L, and Goldblum SE (1995) Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 96:710-720.
6. Furukawa H, Nakamura K, Zheng X, Tojo M, Oyama N, Akiba H, Nishibu A, Kaneko F, Tsunemi Y, Saeki H, et al. (2004) Enhanced TARC production by dust-mite allergens and its modulation by immunosuppressive drugs in PBMCs from patients with atopic dermatitis. J Dermatol Sci 35:35-42. (Pubitemid 38759739)
7. Hokaiwado N, Takeshita F, Banas A, and Ochiya T (2008) RNAi-based drug discovery and its application to therapeutics. IDrugs 11:274-278. (Pubitemid 351481700)
8. Hou YW, Chan MH, Hsu HR, Liu BR, Chen CP, Chen HH, and Lee HJ (2007) Transdermal delivery of proteins mediated by non-covalently associated arginine-rich intracellular delivery peptides. Exp Dermatol 16:999-1006. (Pubitemid 350168123)
9. Kupper TS (1990) Immune and inflammatory processes in cutaneous tissues. Mechanisms and speculations. J Clin Invest 86:1783-1789.
10. Lopes LB, Brophy CM, Furnish E, Flynn CR, Sparks O, Komalavilas P, Joshi L, Panitch A, and Bentley MV (2005) Comparative study of the skin penetration of protein transduction domains and a conjugated peptide. Pharm Res 22:750-757. (Pubitemid 40768587)
11. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, et al. (1997) In vivo transfection of cis element "decoy" against nuclear factor-κB binding site prevents myocardial infarction. Nat Med 3:894-899. (Pubitemid 27353450)
12. Nakamura H, Aoki M, Tamai K, Oishi M, Ogihara T, Kaneda Y, and Morishita R (2002) Prevention and regression of atopic dermatitis by ointment containing NF-κB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Therapy 9:1221-1229.
13. Partidos CD, Beignon AS, Mawas F, Belliard G, Briand JP, and Muller S (2003) Immunity under the skin: potential application for topical delivery of vaccines. Vaccine 21:776-780. (Pubitemid 36091996)
14. Proksch E, Brandner JM, and Jensen JM (2008) The skin: an indispensable barrier. Exp Dermatol 17:1063-1072.
15. Robbins PB, Oliver SF, Sheu SM, Goodnough JB, Wender P, and Khavari PA (2002) Peptide delivery to tissues via reversibly linked protein transduction sequences. BioTechniques 33:190-192, 194.
16. Schäcke H, Döcke WD, and Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23-43.
17. Song KH, Fasano A, and Eddington ND (2008) Enhanced nasal absorption of hydrophilic markers after dosing with AT1002, a tight junction modulator. Eur J Pharm Biopharm 69:231-237. (Pubitemid 351467172)
18. Tanaka A, Muto S, Jung K, Itai A, and Matsuda H (2007) Topical application with a new NF-κB inhibitor improves atopic dermatitis in NC/NgaTend mice. J Invest Dermatol 127:855-863. (Pubitemid 46434644)
19. Tanaka K, Kanazawa T, Shibata Y, Suda Y, Fukuda T, Takashima Y, and Okada H (2010) Development of cell-penetrating peptide modified MPEG-PCL diblock copolymeric nanoparticles for systemic gene delivery. Int J Pharm 396:229-238.
20. Uchida T, Kanazawa T, Kawai M, Takashima Y, and Okada H (2011) Development of an efficient siRNA transdermal delivery system using functional peptides, Tat and AT1002. Chem Pharm Bull (Tokyo) 59:196-201.
21. Watts T, Berti I, Sapone A, Gerarduzzi T, Not T, Zielke R, and Fasano A (2005) Role of the intestinal tight junction modulator zonulin in the pathogenesis of type 1 diabetes in BB diabetic-prone rats. Proc Natl Acad Sci USA 102:2916-2921. (Pubitemid 40299891)